Overview

* Paysign ( PAYS ) Q3 revenue grows 41.6% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats consensus, reflecting improved operational efficiency

* Pharma patient affordability revenue grows 141.9%, driving overall revenue growth

Outlook

* Paysign ( PAYS ) expects full-year 2025 revenue between $80.5 mln and $81.5 mln

* Company anticipates flat plasma revenue in Q4 2025

* Paysign ( PAYS ) projects full-year 2025 Adjusted EBITDA between $19 mln and $20 mln

Result Drivers

* PHARMA REVENUE GROWTH - Pharma patient affordability revenue increased 141.9% yr/yr, driven by 39 net new programs and increased fees

* PLASMA REVENUE GROWTH - Plasma revenue increased 12.4% yr/yr, supported by 117 net new plasma centers despite lower average revenue per center

* SERVICE EXPANSION - New customer service contact center expanded support capacity fourfold, aiding in meeting surging demand

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $21.60 $19.92

Revenue mln mln (5

Analysts

)

Q3 EPS $0.04

Q3 Net $2.22

Income mln

Q3 Beat $5.04 $4.60

Adjusted mln mln (5

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the business support services peer group is "buy"

* Wall Street's median 12-month price target for Paysign Inc ( PAYS ) is $9.00, about 42.7% above its November 11 closing price of $5.16

* The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 47 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)